TNF and inflammatory bowel disease: This can be detrimental for IBD patients who are dependent on anti-TNF regimens because of fistulizing CD [3] or a TNF pathway-dominant disease with immunogenic secondary LOR to TNF blockage, especially if the patient is already treated with a second-line anti-TNF and a third-line anti-TNF agent is not an option.